C3:Momentum

LEGISLATIVE BEAT

5, ISSUE 4
VOLUME 3, 1 Winning the fight better
Moving towards against colorectal
care cancer
and a cure WINTER 2008
SUMMER 2010

Clinical Trials: State-of-the-Art Care Today,

New Hope for Tomorrow
By Mary Mitiguy Miller  Amy Sears knew about clinical trials
because, as a software engineer at the
They’ve been called the unsung heroes
Minnesota Mayo Clinic, she had tested
of modern medicine--those who
computer programs for collecting
voluntarily join clinical trials testing
clinical trial data. But as a 34-year-

PHOTO BY JOE KANE, MAYO CLINIC

new treatments or procedures.  
Most people assume that these heroes
volunteer for clinical trials only
because they have very advanced
cancer that hasn’t responded to any
other treatments.
Not true. Amy Sears, for example,
had undergone successful surgery
for colon cancer and was starting six
months of chemotherapy to further
decrease the chance of recurrence
when she agreed to join a clinical trial.   for future patients. They just want the
In fact, clinical trials can be an option
for people at all stages of disease
or health.  Of the more than 250
colorectal cancer trials currently
underway in the U.S., many are testing
ways to prevent or detect very early
cancer. One trial is testing a vaccine
that would recognize precancerous
protein in polyps and trigger the
person’s immune system to destroy
the polyps before cancer develops.
Another trial is comparing different
imaging techniques to find which tests
(and frequency of tests) best detect
new or recurrent cancer.   get the ‘real’ treatment,” adds Kate
Yet many trials are delayed or even
cancelled because researchers can’t
find enough participants. Only 3 to 5%
of cancer patients participate in trials.
old mother of two young children,
she certainly didn’t expect to need a
cancer trial. However, one Monday at
work she had severe abdominal pain.
Exactly one week later she was in
surgery for colon cancer.  
“I thought it was the end of my life,” Jessica Mitchell (left), oncology nurse
she remembers. Like Amy, most newly practitioner at the Mayo Clinic made sure
diagnosed patients are overwhelmed that patient Amy Sears (right) had all the
with fear and not ready to think about information needed before deciding to join a
clinical trial.
a clinical trial to improve treatments
best possible care to help save their
lives. 
That’s exactly why Dr. Rocky Morton, IN THIS ISSUE
a community oncologist in Des Moines,
Iowa, considers clinical trials for most FROM THE
of his patients at the time of diagnosis.
PRESIDENT’S DESK.........................2
“I believe that patients in clinical trials
can truly get better care,” he says. “If PREVENTION
the doctor and patient are involved in a Screening Saves Lives....................3
trial, it ramps up the care.”  
POLICY
“Many people think that in a clinical Meet Catherine Knowles...............4
trial, some patients just get a ‘placebo’
(no real treatment) while others ADVOCATES IN ACTION.................5
Murphy, C3’s Director of Research C3 thanks Genentech BioOncology for an
unrestricted charitable grant which made
Communication and herself a 25-year
this issue of Momentum possible. C3 is solely
responsible for newsletter content.
continued on page 6

1414 Prince Street, Suite 204, Alexandria, VA 22314

(703) 548-1225 • www.FightColorectalCancer.org

Board of Directors
Nancy Roach, Board Chair
Alan Balch, Ph.D., Vice Chair
Steven Depp, Ph.D., Treasurer
Robert Erwin, Board Secretary
Carlea Bauman, President
Gordon Cole
Medical Review Network
Nancy Baxter, MD, FRCSC
University of Toronto
Al B. Benson III, MD, FACP
Northwestern University
Richard Goldberg, MD
University of North Carolina
Axel Grothey, MD
Mayo Clinic College of Medicine
Heinz-Josef Lenz, MD, FACP
University of Southern California
John Marshall, MD
Georgetown University Medical
Center
Howard McLeod, PharmD
University of North Carolina
Neal Meropol, MD
Fox Chase Cancer Center
Edith Mitchell, MD
Thomas Jefferson University
Daniel Sargent, Ph.D.
Mayo Clinic College of Medicine
Joel Tepper, MD
University of North Carolina
2009 Annual Report
To obtain a copy of C3’s 2009 Annual
Report contact Jerri Lyn Mooney at
1-703-548-1225
x10 or you can
download a copy
at http://link.
2009 ANNUAL REPORT
FightCRC.org/
09AnnualReport.
2 www.FightColorectalCancer.org
FROM THE PRESIDENT’S DESK
Thanks for a Year of
Friendships and Successes
By Carlea Bauman
President
Although C3 is still considered a young
organization (we’ll be starting our
fifth year in March), our friends and
advocates feel like old, dear friends
to us. And as we finish off 2009, it’s
nice to remember all that we’ve been
through together.
We’ve marched on Congress, we’ve
flooded the phone lines to the Capitol,
we’ve put new research dollars
toward beating late-stage colorectal
cancer and we’ve held companies and
government agencies accountable to
patients.
C3 is changing the landscape for
colorectal cancer patients. We are able
to do this because of the support we
receive from you, our friends. Thank
you for all that you have done to
forward the colorectal cancer cause,
and all that you have done to help C3
become the organization it is today.
In the past six months, we said
goodbye to Joe Arite, C3’s Policy
Director since 2007, who left the
organization to follow his heart to
Chicago. We were thrilled to find a
wonderful addition and perfect fit in
Catherine Knowles, C3’s new Director
of Policy (page 4).
We provided another young researcher
the opportunity to make a difference
in colorectal cancer by awarding
our second Lisa Fund Research
grant to Dr. Jeffrey Chou, who is
studying colorectal cancer stem cells.
The search for the third Lisa Fund
Research grant recipient is underway
right now, and will be announced next
spring. One hundred percent of the
grant funding came from C3 donors,
and 100 percent of it went directly
to Dr. Chou. By the end of 2010, C3
will have committed nearly $100,000
to research for late stage colorectal
cancer (www.FightColorectalCancer.
org/LisaFund).
We’re looking forward to seeing
old friends and making new ones at
the 2010 Call-on Congress in March
(page 5 and back cover). We hope
that anyone touched by colorectal
cancer in any way – as a patient,
caregiver, family member, friend or
medical professional – will come to
Washington, DC to have their voices
heard. Our empowering and inspiring
event has had a major impact on
colorectal cancer legislation and
research funding.
On a personal note, I am thrilled to
announce that in August, my husband
and I adopted a baby girl. I took some
time off in the fall to spend with our
new daughter — time that I cherished
immensely. The C3 staff and Board of
Directors didn’t skip a beat while I was
knee deep in formula and diapers for
three months. They have my unending
gratitude for picking up the extra work
with humor, grace and overwhelming
generosity. I returned to work full time
in November.
So, please join us as we celebrate our
successes, which could not have been
achieved without your support and
generosity. We also remember those
who have lost their fight and in their
memory we will work even harder.
May you all have a wonderful holiday
season and a happy new year.
 PREVENTION
LEGISLATIVE BEAT
Screening Saves Lives: Do It
By Carlene Canton
The facts are clear: screening for
colorectal cancer saves lives by
detecting the cancer at early stages
when it can be successfully treated.
Even better: screening prevents
colorectal cancer by detecting and
removing the polyps that can turn into
cancer.
President Obama said as much in his
speech before the joint session of
Congress in September,
“...There’s no reason we shouldn’t
be catching diseases like breast
cancer and colon cancer before
they get worse. That makes sense,
it saves money, and it saves lives.”
Eric Vogt, 67, is one colorectal cancer
patient who is glad the word is finally
getting out. He offers his own story as
a case in point. He firmly believes that
a colonoscopy in 2008 that found stage
III colon cancer saved his life. He only
wishes he had gotten a colonoscopy
ten years earlier.
Eric’s is a cautionary tale. He offers
words of warning to people over the
age of 60 who a decade or more ago
may have initially been told that a
flexible sigmoidoscopy (flex sig) once
every ten years was all they needed to
protect themselves from colon cancer.
“A flex sig only looks at the first 18
inches of the colon. A colonoscopy
looks at the entire colon, and will find
polyps or cancer beyond the reach of
the flex sig.”
When he turned 50, Eric wanted to get
a colonoscopy, because his brother’s
colonoscopy had revealed polyps. But
his insurer didn’t cover colonoscopy as
a routine screening tool and he had a
flex sig screening instead.
Fifteen years later, after he turned
65, he had a Medicare-covered
colonoscopy. That’s when he found
C3 Momentum Winter 2010
Eric Vogt cherishes time with his
grandchildren.
that he had stage III colon cancer
located on the right side of his colon,
beyond the reach of the flex sig.
His doctors told him the cancer
was slow-growing, and had it been
discovered 10 to 15 years earlier, it
could have been easily removed –
maybe even at the polyp stage. In
that case, he likely would never have
developed colon cancer at all.
Eric was no stranger to the earth-
shattering news of a cancer diagnosis.
Six years ago, at age 61, he was
diagnosed with stage III multiple
myeloma.
Eric spent three years in rigorous
treatment for myeloma, a cancer he
believes he contracted after decades of
firefighting, in which he was exposed
to toxins and pesticides, including
Agent Orange. His multiple myeloma
has been in remission since 2004.
But the retired firefighter is not one to
look back. Instead, he looks forward:
to remission, to future screenings and
to spreading the word to his family
and friends that colorectal cancer
screening saves lives.
It wasn’t all that long ago that people
didn’t discuss breast cancer in polite
Screening
Recommendations
In a perfect world everyone who needs
a screening colonoscopy would be able
to get one, covered by insurance and
performed by a highly experienced
medical team. We are not there yet.
“Any screening is preferable to no
screening,” says Dr. Heinz-Josef
Lenz, Professor of Medicine in the
University of Southern California
(USC) Departments of Medicine and
Preventive Medicine, and Co-Director of
the Colorectal Center at the USC/Norris
Comprehensive Cancer Center.
While “colonoscopies are the gold
standard of screening,” says Dr Lenz,
there are alternative screening methods
available. The United States Preventive
Services Task Force recommends the
following minimum screening schedule
for adults 50 to 75 years of age: (1) a
screening colonoscopy every ten years,
(2) a sigmoidoscopy every five years
with high-sensitivity stool tests every
three years or (3) a high-sensitivity stool
test for hidden blood done yearly.
Family history or any positive test
results may require a different screening
schedule.
To read more, check the United
States Preventive Services Task Force
screening recommendations at http://
link.FightCRC.org/crcscreen.
society, and many to this day are
uncomfortable mentioning colon,
rectal, or anal cancer out loud. As a
true believer that screening saves lives,
Eric isn’t shy talking about colorectal
cancer. “A lot of people don’t want
to talk about colon cancer and, as
a result, people could have a family
history of it without even being aware
of it,” he said.
That was the case in his own family.
He learned that an uncle and a
cousin both had advanced colorectal
continued on page 7
3
 POLICY & ADVOCACY
New C3 Policy Director: Not a New Kid in Town
By Mary Mitiguy Miller
C3’s new Director of Policy, Catherine
Knowles, will be on familiar ground as
she directs advocates through the halls
of Congress and monitors legislation
that impacts colorectal cancer
patients. After she graduated from
law school, Catherine spent five years
working on Capitol Hill before joining
C3 in September.
In her former role as legislative
counsel for Rep. Kay Granger (R-TX),
Catherine was in the thick of health
care issues facing Congress. Rep.
Granger sits on the Appropriations
Committee which funds the National
Institutes of Health (NIH) and the
Centers for Disease Control and
Prevention (CDC), and also leads
several health-related initiatives such
as the Congressional Prevention
Caucus.
Rep. Granger lost her father to
colorectal cancer, and has made
colorectal cancer one of her top
priorities. She first introduced the
Colorectal Cancer Prevention, Early
Detection, and Treatment Act (H.R.
1189) in July 2006, and a part of
Catherine’s job was to keep the bill
moving forward. H.R. 1189 will create
a national colorectal cancer screening
program, making this lifesaving
measure available to poor, uninsured
and underinsured Americans.
Because H.R. 1189 is also one of
C3’s top priorities, Catherine had
worked closely with Joe Arite, C3’s
former Director of Policy, to increase
support for the legislation. When Joe
relocated to Chicago in September
2009, Catherine saw it as a perfect
opportunity to join C3 where she could
apply her years of experience with
political and regulatory processes to
focus on just one issue: colorectal
cancer.
Catherine was already impressed
with C3’s advocates, having heard
4 www.FightColorectalCancer.org
Catherine Knowles, C3 Director of Policy
from other legislative staffers how
they brought their personal stories to
Capitol Hill during Call-on Congress
and stood out (in their resplendent
Cover Your Butt T-shirts) from the
usual daily blur of lobbyists and
visitors.
“Legislators are so impressed by
constituents who use their vacation
time and their own money to come
all the way to Washington,” she
said. “Their passion and personal
stories have a far greater impact than
lobbyists paid to cruise the halls of
Congress.”
This March, it will be Catherine
training and escorting C3 advocates
to visit elected officials to tell their
stories as part of 2010 Call-on
Congress on March 15-18. “I’m looking
forward to working with advocates
from across the country to get H.R.
1189 passed this session,” she says.
As a graduate of Indiana
University Law School, Catherine
has also worked at the Federal
Communications Commission and
the National Telecommunications
& Information Administration. Her
familiarity with the inside workings
of regulatory agencies will come
in handy at C3, where part of her
job is to monitor issues affecting
colorectal cancer patients at federal
agencies such as the Food and Drug
Administration.
Catherine blogs and posts political
Action Alerts frequently on C3’s
website. She holds monthly meetings
with the Grassroots Action Committee,
plus quarterly conference calls with
C3 advocates all over the country.
She is available by phone or email if
people want advice about local, state
or federal political action. She can be
reached by telephone at 1-703-548-1225
x12 or by email at Catherine.Knowles@
FightColorectalCancer.org.
“C3 has an outstanding reputation
as a group that has accomplished a
tremendous amount in a short period
of time,” Catherine said. “It is an honor
to be part of a group that not only pays
attention to the science of colorectal
cancer, but also knows how to rally the
troops and impact change.”
Call-on Congress
What: Two-plus days that include
training, networking and visiting
Congress
When: March 15–18, 2010
Who: Patients, caregivers, family, friends
and medical professionals
Cost: $150 plus travel and lodging
Deadline: Application deadline is
Feb. 1, 2010
To register, visit
http://link.FightCRC.org/ConC2010
 POLICY & ADVOCACY
Advocates in Action: Meet Pam Seijo
By Carlene Canton
C3’s newest vice chair of the
Grassroots Action Committee is Pam
Seijo, an author, former teacher,
mother of two and resident of
West Virginia. Pam takes over the
reins of this advocacy committee
from outgoing vice chair Marilia
Sardinha. Momentum readers will be
hearing from Pam in future issues.
Here is her story.
Faith. Hope. Inspiration. Great words
for anyone to live by. But for Pam Seijo
these have been words to cling to since
her long journey with colorectal cancer
began.
She had been in pain for some time.
Finally, one early morning in August of
2000, the pain was so severe that she
rushed to the emergency room. There
she learned that her colon had ruptured
due to a very large rectal tumor that had
broken through the colon wall.
Her body was in so much stress that
doctors had to stabilize her before even
attempting surgery. Once in surgery they
discovered the tumor was far too large
to remove and did their best to repair
the colon and performed a temporary
colostomy.
Pam spent four days in and out of
consciousness after surgery and then
began six weeks of chemotherapy and
34 radiation treatments, all aimed at
shrinking the tumor so that it could be
removed.
At the end of that ordeal she got the
heartbreaking news that the tumor had
actually grown in size and remained
inoperable. Her doctors were out of
ideas.
That’s when Pam added “determination”
to her list of words. After much
searching she located a surgeon at
the University of Virginia who felt that
while the tumor seemed inoperable, the
benefits of surgery outweighed the risks.
C3 Momentum Winter 2010
Pam Seijo, Grassroots Action Committee
Vice Chair
On Dec. 27, 2000 Pam received what
she described as “the best Christmas
gift ever” when her doctor, an
oncology colorectal surgeon, along
with a gynecological oncologist and
a urologist performed an eight-hour
surgery. What they had discovered
days prior to the surgery was sobering
to anyone in the oncology field. Pam’s
tumor had attached itself to the uterus,
to the vaginal wall, and to the bottom
of the spinal column. The surgeons
repositioned the bladder, performed a
complete hysterectomy, removed the
tumor, the rectum and most of the colon
and made that temporary colostomy
permanent.
The need for aggressive treatment
didn’t end there. More chemotherapy
continued over the next 18 months
during which Pam felt sick much of
the time, suffering from hand-foot
syndrome, diarrhea and a long list of
other complications.
Eventually the doctors decided to
put her on a long-term, low-dose of
Xeloda® (capecitabine) which she will
continue for the rest of her life.
While she is proud of surviving this
aggressive cancer and treatment, Pam
is equally proud of the fact that she
continued on page 7
Join Pam Seijo for C3’s
2010 Call-on Congress
As one of her primary goals this year,
Pam wants to increase state-by-state
participation in the 2010 Call-on
Congress. “We had advocates from 17
states and Washington, D.C. in 2009 and
I want to boost that for the 2010 event.”
Each year C3 advocates spend a day in
training and then head up to Capitol
Hill to “Call-on Congress.” C3 sets up
meetings so that the advocates can talk
with their elected officials to push for
issues like a national screening program
and increased funding for colorectal
cancer research. The next Call-on
Congress is set for March 15-18, 2010.
It’s a powerful experience, Pam said.
“I’ve seen people attend a Call-on
Congress training session scared and
intimidated by the thought of visiting
Congress. By the time they leave, they
are able to raise their voices effectively,
and have made great friends.”
States with Call-on Congress
participants in 2009 are listed below.
If your state is not represented, you
can make a difference by meeting with
your elected officials. If your state is
listed, join the team! The deadline for
registration for 2010 Call-on Congress is
February 1, 2010.
States with Call-on Congress
participants in 2009 included: Alabama,
Arizona, California, Florida, Maine,
Maryland, Minnesota, New Hampshire,
New Jersey, New York, North Carolina,
Ohio, Oregon, Pennsylvania, Texas,
Virginia, Washington, D.C., West Virginia.
5
 MEDICAL
Clinical Trials: State-of-the-Art Care Today,
New Hope for Tomorrow
continued from page 1
survivor of both breast and colon
cancer. “That’s not true. All patients
get state-of–the-art treatment, plus
some get an additional experimental
intervention.”   patients can resign from a trial at any
In Amy’s case, her surgery successfully
removed all of the tumor in her colon.
Medical oncologist Dr. Steven Alberts
from the Mayo Clinic recommended
six months of chemotherapy to
decrease chances of recurrence. He
also mentioned the possibility of a
clinical trial testing a new medicine
to ease the side effects of peripheral
neuropathy (painful tingling in
fingers and toes) common with her
chemotherapy.  a distant site. “We have more than
Oncology nurse practitioner and
study coordinator Jessica Mitchell
“spent plenty of time, sitting down
with me and going through all the
information,” Amy said. When she
was assigned to the group receiving
standard chemotherapy plus the new
experimental drug, she felt like it was
no big deal. She said, “When I came
in for chemo, they just hung another
intravenous bag.” At each visit, she
answered an extra questionnaire
about side effects. Two years after her
treatment, Amy remains cancer-free. 
Some clinical trials, Kate Murphy
explains, can require extra tests or
follow-up appointments. Your doctor
will have more paperwork to track
symptoms and data. “People will be
watching you very carefully. You’ll be
checked often for side effects, and
someone has already thought hard
about different ways to respond to
those side effects.”  
Both Kate and Dr. Morton serve on
national committees overseeing the
design and progress of clinical trials all
over the United States, and Kate says
it’s important for people to remember
that an independent committee
monitors the health of patients at
6 www.FightColorectalCancer.org
all trial sites. If patients aren’t being center.” Research results are also more
helped by the trial, the monitoring meaningful when the research includes
committee can stop the trial early. people of diverse backgrounds from all
Equally as important, she adds, is that over the country.
For Amy, the clinical trial was just an
time, for any reason. added part of her care. “I think it’s well
People often believe they must live worthwhile for patients to consider it
near a university or major medical for themselves—and for the education
center to participate in clinical and research of cancer,”  she said. 
trials. Not so, says Dr. Morton, who “Every little bit helps to advance to the
is nationally known for his work at next cure or helpful remedy.” 
 
moving research findings quickly into
community practice. Local oncologists
conduct clinical trials in the patient’s RESOURCES
own community and provide ongoing
• Call C3’s Answer Line
care if the patient chooses a trial in (1-877-4CRC-111) for information
and/or referral to a clinical trial-
100 clinical trials going on in our area matching service
alone. Virtually everyone in Iowa
lives within 30 miles of a community • Keep up with Kate Murphy’s updates
oncologist who can participate in on research and trials at
trials.”  www.FightColorectalCancer.org/
research_news
Clinical trials benefit both patients
and their local doctors, he adds. • Learn more about clinical trials at
“Clinical trials give us the ability to www.Cancer.gov/ClinicalTrials/
provide our patients some of the latest learning
care that otherwise they wouldn’t
get unless they traveled to a cancer
QUESTIONS TO ASK
As a long-time survivor, as well as a research and patient advocate, C3’s Kate Murphy
suggests the following specific questions:
• When choosing a cancer specialist, ask: “Does this office offer clinical trials? If not, would
the doctor be willing to participate if I join a trial that could be done locally?”
• When considering treatment options, ask: “What trials are available for my stage of
disease?”
• If considering a specific trial, be sure the trial’s goals work with your own goal. Small
Phase I trials have very different goals than large, national Phase III trials.
• Clarify what a trial requires (tests, appointments) compared to standard treatment.
• Who pays? Medicare and many insurances pay for ‘customary treatment,’ with the trial
covering extra care or experimental medicines. But that’s not always true, especially for
Phase I trials. Check ahead.
Screening Saves Lives. Do It.
continued from page 3

cancer years before—which would
have strengthened his case for getting
an earlier colonoscopy. He believes
screening has saved all of his siblings.
All had colonoscopies and as a result
some had early polyps removed. None
has developed colon cancer.
As a result, he shares his story every
day of his life.
“I talk about colon cancer to everyone.
I don’t think there’s a single person
who knows me who doesn’t know my
experience with it,” he said. He talks
to family, to friends and to fellow
members at Rotary meetings. “I’ll just
get up and ask: ‘how many of you have
had your colonoscopy?’ I just tell them
to save themselves some pain and
anguish and get it done.
“How can we not do something that we
know saves lives?”
Today, with both his colorectal cancer
and multiple myeloma under control
or in remission, Eric Vogt is retired and
enjoying his life in southern California
with his two sons and six grandchildren
nearby.
When he thinks about how much
he almost lost he comes to only one
conclusion.
“Colonoscopies save lives. Get one.”

Advocates in Action: Meet Pam Seijo A Cherished Year

continued from page 5
never stopped being a mom to her two
children who were 11 and 13 at the
time of her diagnosis.
“I just made the choice to keep going,”
she said. “When I was nauseous,
I attended my son’s games with a
bucket in hand. I did not miss my
daughter’s cheerleading events and
competitions, or her ballet or tap
recitals. I didn’t feel great but I figured
as long as I was still here I was going
to make it to the events that are such a
part of their childhood.”
Along the way, Pam became a
published author, transforming a daily
journal into a book published in 2003:
A Mirrored Image: A Story About
Cancer and Survival.
“I believe the reason I was diagnosed
with cancer and survived is to share
my story and share a message about
hope,” she said.
Outgoing vice chair of C3’s Grassroots
Action Committee Marilia Sardinha
offers a few words about what the past
year has meant to her:
“C3 has made a significant impact in my
life. I have made lifelong friendships with
other advocates, shared my story and
have tried to make a difference along
the way. My relationship with C3 is a gift
that I cherish.”
Readers can meet Marilia and Pam and
other advocates at C3’s 2010 Call-on
Congress in March.

C3’s Work Honors and Remembers Our Loved Ones

C3 receives donations that honor the work and the lives of patients
and advocates fighting colorectal cancer.
We also receive donations in memory of people who have lost their
battle with colorectal cancer, and whose family and friends chose to
remember them and their courage through a donation to C3.
Following are the names of people who have been honored or
memorialized by donors between April and October 2009.
Donations include support for C3’s Lisa Fund, which directly funds
research. Visit www.FightColorectalCancer.org/LisaFund for more
information.
For information about honoring or remembering a loved one,
contact Ben Basloe, Director of Development at Ben.Basloe@
FightColorectalCancer.org or by phone at 1-703-548-1225 x17.
Donations to C3 can go farther when corporate matching funds
are available. Ask Ben for more information.

WE HONOR AND REMEMBER

italics indicate memorial donations

Steve Baker • Ted Blau • Joe Casone • Nancy Crafts • Janet Crane • Edmond Dowe • Lisa Dubow • Avi Elbachri
Anthony Evans • Fran Hagin • Arlene Hartill • Ian Harvey • Bill Keane • Rae Ann Littler • Joan Maddox • Patricia Ann Martins
Kevin May • David Moskal • Christine Niemi • Patricia Pagliaro • Henrietta Ryder • Christine Teepe • Kenneth Weiner

C3 Momentum Winter 2010 7

 NONPROFIT
U.S. POSTAGE
PAID
STAMFORD, CT
1414 Prince Street PERMIT NO. 102
Suite 204
Alexandria, VA 22314

Register to receive future

issues of Momentum at
www.FightColorectalCancer.org

To make corrections to your contact

information or to remove your name from
the mailing list, please email
info@FightColorectalCancer.org or
call 1-703-548-1225.

CALL-ON CONGRESS REGISTRATION NOW OPEN

March 15-18, 2010

“Change doesn’t come from Washington. 
Change comes to Washington.”
President Barack Obama

Imagine yourself in the Halls of Congress...fighting for an end to

colorectal cancer. You CAN do it, and we are here to help.
C3 is proud to bring advocates together from around the country
to participate in our fourth annual training program and colorectal
cancer advocacy day. We invite you to register to join us and let your
voice be heard.
This is your chance to meet fellow colorectal cancer advocates,
develop the skills you need to be a great advocate back home, and
learn what Congress’ role is in fighting this terrible disease. Most
important, you’ll conclude your visit by putting what you learn into
practice on Capitol Hill in meetings with your Members of Congress
and their staff. We will provide you with the tools and training you
need to be a successful advocate, so that your voice can bring
change to Washington!
C3 Board Member Gordon Cole (right)
http://link.FightCRC.org/ConC2010 with Rep. Howard Coble, (R-NC) at the
2009 Call-on Congress.

8 www.FightColorectalCancer.org